The facts
Abridge at a glance.
Read Oct 20, 2026. Valuations and amounts are copied as each source states them; a figure that is only reported (talks, or people familiar with the deal) is labeled as reported.
Founders
- Shiv Rao: cardiologist (per TechCrunch) (TechCrunch, Jun 24, 2025)
Announced Eli Lilly strategic investment, a clinician platform, an NVIDIA co-developed model and an Artisight partnership Jun 11, 2026
Fortune, Jun 11, 2026
What it has built
Shipped, or not yet.
“Has a product” is what our search found: something the public can use or buy, a model or API, research only, or nothing public.
Foundation model for clinical conversations, co-developed with NVIDIA (announced)
Source4 rounds
Funding, as reported.
Every round we found, with the amount, valuation and investors as the source states them.
| When | Round | Amount | Valuation | Investors named | Source |
|---|---|---|---|---|---|
| Feb 2025 | unnamed | $250 million | $2.75 billion | None named | TechCrunch |
| Jun 24, 2025 | Series E | $300 million | $5.3B | Andreessen Horowitz (lead), Khosla Ventures | TechCrunch |
| Apr 2026 | Series E extension | $316 million | $5.3 billion | None named | Fortune |
| Jun 11, 2026 | strategic investment | Not stated | Not stated | Eli Lilly | Fortune |
Our note
Worth knowing.
Our note: Founded in 2018, before the 2020 cut-off in STARTUPS-SHAPE.md; included only because the brief named it as an example. Drop it if the cut-off is strict. Fortune is not on the trusted-outlet list; figures match TechCrunch's 2025 report where they overlap. The Information-sourced ARR figure in TechCrunch ($117 million contracted ARR, Q1 2025) includes customers not yet onboarded.
More law, medicine, finance and defense